My ePortfolio Register   

Molecular medicine in lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 390

Dr Reinhard Büttner - University Hospital of Cologne, Cologne, Germany

Dr Büttner speaks with ecancer at WIN 2017 about determining vulnerabilities to targeted or immune therapeutics in lung cancer through Network Genomic Medicine.

He discusses the landmark successes of PD-1 checkpoint therapy for lung cancer, and futher mutational markers of resistance and vulnerability.

Dr Büttner considers the comparable incidence of lung cancers resulting from germ-line mutation and those arising from environmental factors, with emphasis on early detection and diagnosis to alleviate disease burden before advanced disease

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence